FSD Pharma announces interim results from FIH trial of Lucid-MS

FSD Pharma announced that an interim report has been received for the first-in-human single ascending dose Phase I clinical trial evaluating the Company’s novel drug candidate Lucid-21-302, an orally-administered treatment for Multiple Sclerosis. This interim blinded report was issued on August 17, 2023 for the first 4 cohorts, with an addendum report describing the results of the fifth cohort due by the end of the month. The report, issued by Biopharma Services Inc. as the clinical research organization under contract to FSD, states that “Lucid-21-302 was demonstrated to be safe and well-tolerated in single oral doses in healthy volunteers. Individual concentrations and PK parameters of Cohorts 1 to 4 are very encouraging for further development activity.”